The GBA Multimodal Study in Parkinson's Disease

Part of paid clinical trials in Portland, Oregon.

Sponsor
Pacific Parkinson's Research Centre
Study ID
NCT04101968
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • PET scan — DIAGNOSTIC_TEST
    3 PET scans to analyze the dopamine metabolism, acetylcholine and tau protein deposition in the brain.
  • neuroQWERTY — DIAGNOSTIC_TEST
    Analysis of free-text typing in a computer and/or a touch-screen device.

Study Details

This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessment to study the typing patterns as possible biomarkers of early motor dysfunctions.

Key Dates

Start date
May 1, 2019
Status verified
May 2025
Primary completion
Dec 30, 2025
Completion
Dec 30, 2025

Study Design

Enrollment
25 participants (estimated)

Arms

  • Arm: GBA-PD
    People with Parkinson's disease who are known heterozygous carriers of pathogenic GBA gene mutations.
  • Arm: Asymptomatic GBA
    Known heterozygous carriers/obligated carriers of pathogenic GBA gene mutations.

Primary Outcome Measure

Acetylcholinesterase activity [ Time Frame: baseline ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Oregon Health & Science UniversityPortlandOregon97239
Matthew Brodsky, MD (PRINCIPAL_INVESTIGATOR)
University of WashingtonSeattleWashington98108-1595
Cyrus P Zabetian, MD, MS (PRINCIPAL_INVESTIGATOR)

Find similar trials in Portland, OR

Related Studies